Hemab Therapeutics Holdings Inc (COAG) FinancialsCOAGHemab Therapeutics Holdings Inc

In the context of the broader market, COAG competes directly with industry leaders such as KMDA and ABSI. With a market capitalization of $1.60B, it holds a significant position in the sector. When comparing efficiency, COAG's gross margin of N/A stands against KMDA's 40.91% and ABSI's 100.00%. Such benchmarking helps identify whether Hemab Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Hemab has reported substantial net losses, with Q2 2026 net income at -24,150,000 USD and an EPS of -0.52, indicating ongoing financial challenges despite the potential for future growth.